EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma: A 20‐year follow‐up

Mateus Trinconi Cunha iD, Matheus Sewastjanow-Silva iD, F Christopher Holsinger iD, Adam S Garden iD, Adel K El-Naggar, Jeffrey N Myers iD, Jan Lewin, Ann M Gillenwater, J Jack Lee iD, Fadlo R Khuri, Eduardo M Diaz iD, Renata Ferrarotto iD

Cancer · 2025

DOI: 10.1002/cncr.70177 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Cancer, 2025. Verfasst von Mateus Trinconi Cunha und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Laryngeal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current treatment options for nonmetastatic laryngeal squamous cell carcinoma include radiotherapy, chemoradiotherapy, and surgery, which can result in significant morbidity. This study reports the 20‐year outcomes of a single‐modality chemotherapy as a larynx preservation strategy in patients with stage II–IVa laryngeal squamous cell carcinoma (LSCC).

Methods

In this single‐institution, single‐arm, prospective clinical trial, 31 patients with stage II–IVa LSCC received three or four cycles of paclitaxel, ifosfamide, and a platinum agent (TIP). Patients with a pathologic complete response (pCR) by biopsy assessment received three additional cycles without local therapy. Patients with a partial response underwent conservation laryngeal surgery (CLS). The primary end point was 2‐year larynx preservation rate (LPR). Secondary end points included recurrence‐free survival (RFS), overall survival (OS), and long‐term complications.

Results

With a median follow‐up time of 21 years, 11 patients (35%) achieved a pCR and were managed with chemotherapy alone. None required laryngectomy, and only one experienced recurrence, which was successfully salvaged with radiotherapy. Among 19 patients who underwent CLS or radiotherapy, seven experienced recurrence and six required laryngectomy. The 20‐year LPR was 72%; median OS was 13.5 years, and median RFS was 10.3 years. Patients with a pCR had significantly fewer long‐term complications, including lower rates of feeding tube and tracheostomy dependence ( p < .01).

Conclusions

This long‐term follow‐up reinforces that TIP alone is an effective larynx preservation strategy in patients with LSCC who achieve a pCR. Further investigations of systemic therapy for laryngeal cancer treatment, including less toxic combinations and immunotherapy as well as incorporating tissue‐ and blood‐based biomarkers, are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellLaryngeal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesIfosfamideLaryngectomyNeoplasm Recurrence, LocalNeoplasm StagingPaclitaxelProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

antineoplastic combined chemotherapy protocolscarcinomacisplatinifosfamidelaryngeal neoplasmslaryngectomyneoadjuvant therapypaclitaxelsquamous cellstreatment outcome

Substanzen

IfosfamidePaclitaxel

Autor:innen und Institutionen

  • Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Head and Neck Surgery, Stanford University, Stanford, California, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Mateus Trinconi Cunha, Matheus Sewastjanow-Silva, F Christopher Holsinger, Adam S Garden, Jeffrey N Myers, J Jack Lee, Eduardo M Diaz, Renata Ferrarotto

Förderung

  • NCI NIH HHS

Zitieren

APA

Trinconi Cunha, M., Sewastjanow-Silva, M., Holsinger, F. C., Garden, A. S., El-Naggar, A. K., Myers, J. N., Lewin, J., Gillenwater, A. M., Lee, J. J., Khuri, F. R., Diaz, E. M., & Ferrarotto, R. (2025). Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma: A 20‐year follow‐up. Cancer. https://doi.org/10.1002/cncr.70177

Vancouver

Trinconi Cunha M, Sewastjanow-Silva M, Holsinger FC, Garden AS, El-Naggar AK, Myers JN, et al. Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma: A 20‐year follow‐up. Cancer. 2025. doi:10.1002/cncr.70177

BibTeX
@article{TrinconiCunha2025,
  author = {Trinconi Cunha, Mateus and Sewastjanow-Silva, Matheus and Holsinger, F Christopher and Garden, Adam S and El-Naggar, Adel K and Myers, Jeffrey N and Lewin, Jan and Gillenwater, Ann M and Lee, J Jack and Khuri, Fadlo R and Diaz, Eduardo M and Ferrarotto, Renata},
  title = {Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma: A 20‐year follow‐up},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70177}
}
Kostenlos starten →